Drug therapy and pharmacogenomics - Hopes and facts;Arzneimitteltherapie und pharmakogenomik - Hoffnungen und fakten

Wiener Medizinische Wochenschrift

Volumn 155, Issue 3-4, 2005, Pages 45-49

  Müller Zellenberg, Ulrike ^a   Müller, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adverse drug reaction; Genotype; Non responder; Pharmacogenomics

Indexed keywords

NEW DRUG;

DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ETHICS; GENETIC ANALYSIS; GENOTYPE; HUMAN; MOLECULAR GENETICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; EXONS; GENOTYPE; HUMANS; INCIDENCE; INTRONS; MUTATION; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 15344341886     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-004-0145-1     Document Type: Review

References (16)

1. Carson PE, Flanagan CL, Ickes CE, Alving AS (1956) Enzymatic deficiency in primaquine sensitive erythrocytes. Science 124: 484-485
2. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439): 487-491
3. Garrod AE (1996) The incidence of alkaptonuria: a study in chemical individuality. Mol Med 2(3): 274-282
4. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331(6155): 442-446
5. Johnson GC, Esposito L, Barratt BJ, Smith AN, Reward J, Di Geneva G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, et al (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29: 233-237
6. Ingelman-Sundberg M (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250(3): 186-200
7. Issa AM (2002) Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 1(4): 300-308
8. Lai E, Bowman C, Bansal A, Hughes A, Mosteller M, Roses AD (2002) Medical applications of haplotype-based SNP maps: learning to walk before we run. Nat Genet 32(3): 353
9. Landsteiner K (2001) Agglutination phenomena of normal human blood. Wien Klin Wochenschr 113(20-21): 768-769
10. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15): 1200-1205
11. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA (1999) Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 65(5): 519-525
12. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308): 727-732
13. Mansmann U, Winkelmann BR (2002) Classification and prediction in pharmacogenetics - context, construction and validation. Pharmacogenomics 3(2): 157-160
14. Müller M (2003) Pharmacogenomics and drug response. Int J Clin Pharmacol Ther 41(6): 231-240
15. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91(23): 2001-2008
16. Schutz E, Gummert J, Mohr F, Oellerich M (1993) Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341(8842): 436